Turn Therapeutics Inc. (TTRX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Turn Therapeutics Inc. (TTRX) Healthcare & Pipeline Overview

Turn Therapeutics Inc., a biotechnology company, develops pharmaceutical products targeting skin, nail, and eye diseases. Their core technology enhances drug delivery and reduces antibiotic resistance, positioning them in the acute and chronic wound care market with a focus on improving treatment efficacy and patient outcomes.

What Is the Investment Thesis for TTRX?

Turn Therapeutics Inc. presents a focused investment opportunity within the biotechnology sector, driven by its proprietary drug delivery technology targeting skin, nail, and eye diseases. The company's emphasis on enhancing penetration and reducing antibiotic resistance addresses critical needs in wound care and dermatology. Key value drivers include successful clinical trials demonstrating improved efficacy and safety, strategic partnerships with healthcare institutions for product adoption, and potential FDA approvals for novel therapies. However, the company's small size and limited resources pose risks, requiring careful monitoring of cash burn rate and funding runway. The market capitalization of $284M reflects the early stage of development and associated uncertainties. Positive clinical data and successful commercialization could drive significant upside, while regulatory setbacks or financial constraints could limit growth.

Based on FMP financials and quantitative analysis

TTRX Key Highlights

Focus on innovative drug delivery technology for skin, nail, and eye diseases.

• Addresses the growing need for solutions to combat antibiotic resistance in wound care.
• Strategic focus on specialized dermatological and ophthalmic applications.
• Market capitalization of $284M reflects the company's early stage of development.
• Potential for significant upside driven by successful clinical trials and FDA approvals.

Who Are TTRX's Competitors?

TTRX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are TTRX's Key Strengths?

Innovative drug delivery technology.

• Focus on unmet needs in wound care.
• Potential for reducing antibiotic resistance.
• Experienced management team.

What Are TTRX's Weaknesses?

Limited financial resources.

• Small employee base.
• Early stage of development.
• Dependence on regulatory approvals.

What Could Drive TTRX Stock Higher?

Announcement of clinical trial results for lead drug candidates.

• Potential FDA approval for novel therapies.
• Strategic partnerships with healthcare institutions.
• Expansion into new dermatological applications.

What Are the Key Risks for TTRX?

Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.

• Regulatory hurdles and delays in obtaining FDA approvals.
• Competition from established pharmaceutical companies.
• Patent expiration risks and generic competition.
• Limited financial resources and dependence on external funding.

What Are the Growth Opportunities for TTRX?

• Expansion into New Dermatological Applications: Turn Therapeutics can leverage its drug delivery technology to develop treatments for a broader range of dermatological conditions, such as psoriasis, eczema, and acne. The global dermatology market is estimated to reach $36.6 billion by 2027, presenting a significant growth opportunity. Successful development and commercialization of new products in these areas could drive substantial revenue growth and market share gains for Turn Therapeutics.
• Strategic Partnerships with Healthcare Institutions: Collaborating with hospitals, clinics, and specialized wound care centers can accelerate the adoption of Turn Therapeutics' products. These partnerships can provide access to a large patient base, facilitate clinical trials, and generate valuable real-world data. By establishing strong relationships with key healthcare providers, Turn Therapeutics can enhance its market presence and build a sustainable competitive advantage.
• Securing FDA Approvals for Novel Therapies: Obtaining regulatory approvals for its lead drug candidates is crucial for Turn Therapeutics' long-term success. FDA approval not only validates the safety and efficacy of its products but also opens up access to reimbursement and broader market adoption. The company's ability to navigate the regulatory process efficiently and secure timely approvals will be a key driver of growth and shareholder value.
• Geographic Expansion into International Markets: Expanding its commercial operations beyond the United States can unlock significant growth opportunities for Turn Therapeutics. The global wound care market is characterized by regional variations in prevalence, treatment practices, and regulatory requirements. By adapting its products and strategies to meet the specific needs of different international markets, Turn Therapeutics can tap into new revenue streams and diversify its geographic footprint.
• Development of Ophthalmic Applications: Leveraging its drug delivery technology to develop treatments for eye diseases represents a promising growth avenue for Turn Therapeutics. The global ophthalmic market is projected to reach $44.9 billion by 2027, driven by an aging population and increasing prevalence of eye disorders such as glaucoma, macular degeneration, and diabetic retinopathy. Successful development of ophthalmic products could significantly expand Turn Therapeutics' addressable market and diversify its revenue base.

What Are TTRX's Competitive Advantages?

• Proprietary drug delivery technology.
• Patents protecting its formulations and methods.
• Focus on reducing antibiotic resistance.
• Specialized expertise in dermatology and ophthalmology.

What Does TTRX Do?

Turn Therapeutics Inc., formerly known as Global Health Solutions, Inc., was founded in 2015 and is headquartered in Westlake Village, California. The company operates as a pharmaceutical entity focused on the research, development, and commercialization of innovative therapies for diseases affecting the skin, nails, and eyes. Turn Therapeutics' core technology is centered around enhancing drug delivery to improve penetration and reduce antibiotic resistance. Their product pipeline addresses a range of conditions, from acute and chronic wounds to various dermatoses. The company aims to provide healthcare institutions with advanced solutions for managing complex skin conditions and improving patient outcomes. By focusing on novel drug delivery mechanisms, Turn Therapeutics seeks to overcome limitations associated with traditional topical treatments and combat the growing challenge of antibiotic resistance in wound care. The company's strategic focus on specialized dermatological and ophthalmic applications differentiates it within the broader pharmaceutical landscape.

What Products and Services Does TTRX Offer?

• Develops pharmaceutical products for skin diseases.
• Creates treatments for nail conditions.
• Researches therapies for eye disorders.
• Utilizes proprietary drug delivery technology.
• Focuses on enhancing drug penetration.
• Aims to reduce antibiotic resistance.
• Offers solutions for acute and chronic wound care.

How Does TTRX Make Money?

• Develops and patents proprietary drug delivery technology.
• Conducts research and clinical trials to validate product efficacy.
• Seeks regulatory approvals from agencies like the FDA.
• Commercializes products through partnerships with healthcare institutions.

What Industry Does TTRX Operate In?

Turn Therapeutics operates within the biotechnology industry, specifically targeting the dermatology and wound care markets. The competitive landscape includes established pharmaceutical companies and smaller biotech firms developing advanced wound care products. Turn Therapeutics differentiates itself through its proprietary drug delivery technology, which aims to improve penetration and reduce antibiotic resistance. The company's success depends on navigating regulatory hurdles, securing partnerships, and demonstrating clinical efficacy in a competitive environment.

Who Are TTRX's Key Customers?

• Hospitals and clinics.
• Wound care centers.
• Dermatologists and ophthalmologists.
• Patients with skin, nail, and eye diseases.

Company Profile

Turn Therapeutics Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Westlake Village, US. The company is led by CEO Bradley E. Burnam. TTRX has traded publicly since 2025.

Turn Therapeutics Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 7.86 places it in the safe zone, indicating low near-term bankruptcy risk.

Key Financial Metrics

Return on assets is -49.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -1.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.19 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -2.9%, the inverse of the P/E and a quick read on earnings relative to price.

TTRX Valuation & Market Position

With a $284M market cap, Turn Therapeutics Inc. sits in the micro-cap segment of the market. Relative to its peer group, TTRX's quantitative score of 47/100 is below the peer average of 78/100.

Wall Street analysts project Turn Therapeutics Inc. revenue of about $500K for fiscal 2026, with EPS near $-0.09.

TTRX Financials

TTRX Latest News

TTRX Analyst Consensus

TTRX MoonshotScore

TTRX Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources